Graham Pockley,
Director and Professor, John van Geest Cancer Research Centre
Professor A. Graham Pockley, PhD is the CEO of multimmune GmbH (www.multimmune.com), Munich, Germany. multimmune’s unique and proprietary technology platform is based on the discovery (by Gabriele Multhoff and Claus Botzler) that a cell surface bound form of Hp70 is selectively and widely expressed on the plasma membranes of many tumour entities. multimmune is developing innovative theranostics on the basis of membrane Hsp70 expression by tumour cells, including an autologous NK cell-based therapy (ENKASTIMev)
Graham Pockley is also Professor of Immunobiology and Director of the John van Geest Cancer Research Centre (JvGCRC) at Nottingham Trent University, Nottingham, UK. The JvGCRC uses integrated genomic, proteomic, immunological and bioinformatics platforms to identify biomarkers of disease and disease progression, predict therapeutic responses and develop diagnostic and immunotherapeutics. Programmes study the orchestration of innate and adaptive immunity in cancer, discover immunological and protein biomarkers of disease and therapeutic responses in cancer, and its findings inform the development and delivery of new diagnostic and immunotherapeutic strategies.
|
|
|
